Dzimitrowicz, H. E., Berger, M. J., Vargo, C., Hood, A., Abdelghany, O., Raghavendra, A. S., … Murthy, R. K. (2016). T-DM1 activity in metastatic HER2-positive breast cancers that received prior therapy with trastuzumab and pertuzumab. In Journal of Clinical Oncology (Vol. 34, pp. 585–585). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2016.34.15_suppl.585

Dzimitrowicz, Hannah Elizabeth, Michael J. Berger, Craig Vargo, Annette Hood, Osama Abdelghany, Akshara Singareeka Raghavendra, Debu Tripathy, Vicente Valero, Lajos Pusztai, and Rashmi Krishna Murthy. “T-DM1 activity in metastatic HER2-positive breast cancers that received prior therapy with trastuzumab and pertuzumab.” In Journal of Clinical Oncology, 34:585–585. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.585.

Dzimitrowicz HE, Berger MJ, Vargo C, Hood A, Abdelghany O, Raghavendra AS, et al. T-DM1 activity in metastatic HER2-positive breast cancers that received prior therapy with trastuzumab and pertuzumab. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. 585–585.

Dzimitrowicz, Hannah Elizabeth, et al. “T-DM1 activity in metastatic HER2-positive breast cancers that received prior therapy with trastuzumab and pertuzumab.” Journal of Clinical Oncology, vol. 34, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2016, pp. 585–585. Crossref, doi:10.1200/jco.2016.34.15_suppl.585.

Dzimitrowicz HE, Berger MJ, Vargo C, Hood A, Abdelghany O, Raghavendra AS, Tripathy D, Valero V, Pusztai L, Murthy RK. T-DM1 activity in metastatic HER2-positive breast cancers that received prior therapy with trastuzumab and pertuzumab. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. 585–585.